Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01508702 · ClinicalTrials.gov registry record · Phase 3
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 study, sponsored by Ardea Biosciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 214
- Enrollment target
NCT01508702 is a Phase 3 study that has completed, run by Ardea Biosciences. The registered enrollment target is 214 participants.
The verdict
NCT01508702, a Phase 3 study, has completed, sponsored by Ardea Biosciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 214 participants
- Enrollment target
Study Summary
This study will assess the serum uric acid lowering effects and safety of lesinurad compared to placebo in patients who are intolerant or have a contraindication to allopurinol or febuxostat.
Interventions
- DRUG Placebo
- DRUG lesinurad
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 214 participants |
| Start Date | 2012-01 |
| Est. Completion | 2013-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01508702
The ClinicalTrials.gov registry entry for NCT01508702 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 214 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ardea Biosciences, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01508702 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01508702 about?
NCT01508702 is a clinical study titled "Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors". This study will assess the serum uric acid lowering effects and safety of lesinurad compared to placebo in patients who are intolerant or have a contraindication to allopurinol or febuxostat.
What is the current status of trial NCT01508702?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 214 participants. The study started on 2012-01. Estimated completion is 2013-11.
What interventions are being tested in trial NCT01508702?
The interventions under investigation include: Placebo (DRUG), lesinurad (DRUG).
Who is sponsoring clinical trial NCT01508702?
This trial is sponsored by Ardea Biosciences, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.